GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

global head of oncology R&D at GSK. “We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

After hours: February 3 at 6:25:46 p.m. EST ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...